Alliance for Multispecialty Research, LLC.
Mobile, Alabama 36608
0 studies enrolling now · 14 studies all time
What they study most
Atherosclerotic Cardiovascular Disease (ASCVD), COVID-19, Cardiovascular Diseases, Chikungunya Virus Infection, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Contraception, Elevated Lp(a), Enteric Hyperoxaluria, Gout, Gout Flare, Hyperuricemia
Studies at this site
- Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination — Running, not enrolling
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
- Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions — Completed
- A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals — Completed
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
- A Study of Cytisinicline for Smoking Cessation in Adult Smokers — Completed
- A Study in Patients With Mixed Dyslipidemia — Running, not enrolling
- Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers — Completed
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive — Stopped early
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients — Completed
- Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed
- Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria — Stopped early